T3 Pharmaceuticals is a technology company.
T3 Pharmaceuticals has raised $39.0M across 2 funding rounds.
T3 Pharmaceuticals has raised $39.0M in total across 2 funding rounds.
T3 Pharmaceuticals is a Swiss biotechnology company that develops highly specific and efficient cancer therapies using live bacteria as delivery vehicles for therapeutic proteins. Their proprietary platform harnesses genetically engineered bacteria that selectively colonize solid tumors and inject bioactive proteins directly into cancer cells, aiming to trigger immune responses or induce cell death. This innovative approach targets solid tumors with precision, addressing the unmet need for novel cancer treatments beyond classical therapies. T3 Pharma has demonstrated strong growth momentum, culminating in its acquisition by Boehringer Ingelheim in 2023 for CHF 450 million, underscoring its clinical and commercial potential[1][2][4][6].
Founded in May 2015 as a spin-off from the University of Basel by Simon Ittig, Christoph Kasper, Marlise Amstutz, and Helmut Kessmann, T3 Pharma emerged from academic research into bacterial type 3 secretion systems. The founders envisioned engineering live bacteria as precise protein delivery systems to treat cancer. Early traction included multiple financing rounds, prestigious awards such as the W.A. de Vigier Foundation’s highest startup award in Switzerland, and significant grants from Swiss cancer research organizations. The company’s technology was published in a leading cell biology journal, validating its scientific foundation and helping attract investor confidence[1][2][4][6].
T3 Pharmaceuticals rides the growing trend of leveraging synthetic biology and live bacterial therapies in oncology, a field seeking more precise, targeted, and immune-activating treatments. The timing is critical as immuno-oncology continues to expand, but many patients still lack effective options for solid tumors. T3’s approach addresses limitations of traditional therapies by combining biological engineering with tumor microenvironment targeting. Market forces such as increasing cancer incidence, demand for personalized medicine, and advances in microbiome science favor T3’s innovation. Their work influences the broader biotech ecosystem by demonstrating the viability of bacteria-based drug delivery platforms and inspiring further research into live microbial therapeutics[1][4][6].
Looking ahead, T3 Pharmaceuticals is poised to advance its lead programs through clinical development under Boehringer Ingelheim’s umbrella, potentially expanding indications and refining its bacterial delivery technology. Trends shaping their journey include growing acceptance of live biotherapeutics, integration of synthetic biology with immuno-oncology, and regulatory evolution for novel modalities. Their influence may extend beyond oncology into other therapeutic areas where targeted protein delivery is beneficial. T3 Pharma’s trajectory from academic spin-off to a major pharma acquisition highlights the transformative potential of engineered bacteria in medicine, setting a precedent for future innovations in cancer treatment[1][2][4][6].
T3 Pharmaceuticals has raised $39.0M in total across 2 funding rounds.
T3 Pharmaceuticals's investors include Boehringer Ingelheim Venture Fund, Soffinova Partners.
T3 Pharmaceuticals has raised $39.0M across 2 funding rounds. Most recently, it raised $27.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $27.0M Series C | Boehringer Ingelheim Venture Fund, Soffinova Partners | |
| Sep 1, 2019 | $12.0M Series B | Boehringer Ingelheim Venture Fund, Soffinova Partners |